{
  "id": "5a7247182dc08e987e000010",
  "type": "summary",
  "question": "Describe mechanism of action of Ozanimod.",
  "ideal_answer": "Ozanimod is a novel, selective, oral sphingosine-1-phosphate (1 and 5) receptor modulator in clinical development for the treatment of chronic immune-mediated, inflammatory diseases, such as multiple sclerosis and inflammatory bowel disease. Yet its exact mechanism of action is unknown.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28398597",
    "http://www.ncbi.nlm.nih.gov/pubmed/26990079",
    "http://www.ncbi.nlm.nih.gov/pubmed/28147349",
    "http://www.ncbi.nlm.nih.gov/pubmed/27144850",
    "http://www.ncbi.nlm.nih.gov/pubmed/28812220",
    "http://www.ncbi.nlm.nih.gov/pubmed/26702336",
    "http://www.ncbi.nlm.nih.gov/pubmed/28765121",
    "http://www.ncbi.nlm.nih.gov/pubmed/28279838",
    "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
    "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
    "http://www.ncbi.nlm.nih.gov/pubmed/26239599",
    "http://www.ncbi.nlm.nih.gov/pubmed/26398681",
    "http://www.ncbi.nlm.nih.gov/pubmed/27049060"
  ],
  "snippets": [
    {
      "text": "The sphingosine-1-phosphate receptor-1 (S1P1) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049060",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finally, the S1P1 receptor agonist ozanimod showed promise in early trials in ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28147349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ntil recently, three S1P modulators with differing selectivity for S1P receptors were in clinical development for IBD: ozanimod (RPC1063), etrasimod (APD334) and amiselimod (MT-1303).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28279838",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod is an oral selective modulator of S1P1Rand S1P5Rreceptors in clinical development for the treatment of chronic immune-mediated, inflammatory diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28398597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod is a novel, selective, oral sphingosine-1-phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Emerging strategies to interfere with cellular adhesion processes involved in lymphocyte recruitment are discussed, including both integrin blockade (natalizumab, vedolizumab, etrolizumab) and sphingosine-1-phosphate receptor inhibition (fingolimod, ozanimod).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28765121",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RECENT FINDINGS: We discuss the most important findings of one published phase II trial that targeted the \u03b27 integrin (etrolizumab), two phase II trials that targeted the \u03b14\u03b27 integrin ligand: mucosal addressin cell adhesion molecule 1 (MAdCAM-1, PF-00547659), a phase II trial targeting the chemokine IP-10 (CXCL10) in Crohn's, and a phase II trial that targeted the sphingosine-1-phosphate receptor-1: ozanimod in patients with ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26398681",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " As such, agents that more selectively target subtype 1 of the S1PR are of interest and are at various stages of development. These include ponesimod (ACT128800), siponimod (BAF312), ozanimod (RPC1063), ceralifimod (ONO-4641), GSK2018682, and MT-1303.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28812220",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ozanimod (RPC1063) is an oral selective modulator of the sphingosine-1-phosphate 1 and 5 receptors under development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ozanimod is a novel, selective, oral sphingosine-1-phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator:",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ozanimod (RPC1063) is an oral selective modulator of the sphingosine-1-phosphate 1 and 5 receptors under development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "<b>BACKGROUND</b>: Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral lymphocyte sequestration, potentially decreasing the number of activated lymphocytes circulating to the gastrointestinal tract.<br><b>METHODS</b>: We conducted a double-blind, placebo-controlled phase 2 trial of ozanimod in 197 adults with moderate-to-severe ulcerative colitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27144850",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "several new medications are being investigated in late phase studies for the treatment of patients with relapsing or progressive multiple sclerosis ms these agents represent a variety of mechanisms of action and provide not only lower relapse rates but also improvement in disabilities the majority of investigational trials involve selective sphingosine 1 phosphate receptor 1 immunomodulators such as laquinimod ozanimod ponesimod and siponimod in an effort to build on the success of fingolimod ocrelizumab is a cd20 positive b cell targeting monoclonal antibody with a promising new mechanism of action ofatumumab is also a cd20 inhibitor daclizumab an interleukin 2 inhibitor has evidence of good efficacy but is associated with unfavorable side effects masitinib is a mast cell inhibitor that also has shown efficacy in alzheimer s disease and amyotrophic lateral sclerosis phase 3 trials for some of these agents will conclude in the next 12 months and their manufacturers are expected to apply for us food and drug administration approval soon thereafter this review article summarizes data for newly approved and late phase investigational agents for the treatment of patients with ms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26702336",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "sphingosine 1 phosphate s1p receptor modulators possess a unique mechanism of action as disease modifying therapy for multiple sclerosis ms subtype 1 s1p receptors are expressed on the surfaces of lymphocytes and are important in regulating egression from lymph nodes the s1p receptor modulators indirectly antagonize the receptor s function and sequester lymphocytes in lymph nodes fingolimod was the first s1p agent approved in the usa in 2010 for relapsing ms after two phase iii trials freedoms and transforms demonstrated potent efficacy and good safety and tolerability post marketing experience as well as a third phase iii trial freedoms ii also showed favorable results more selective s1p receptor agents ponesimod act128800 siponimod baf312 ozanimod rpc1063 ceralifimod ono 4641 gsk2018682 and mt 1303 are still in relatively early stages of development but phase i and ii trials showed promising efficacy and safety however these observations have yet to be reproduced in phase iii clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26239599",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "results from the first in human study with ozanimod a novel selective sphingosine 1 phosphate receptor modulator",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28398597",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "cardiac safety of ozanimod a novel sphingosine 1 phosphate receptor modulator results of a thorough qt qtc study",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "effects of high and low fat meals on the pharmacokinetics of ozanimod a novel sphingosine 1 phosphate receptor modulator",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "ozanimod rpc1063 is a potent sphingosine 1 phosphate receptor 1 s1p1 and receptor 5 s1p5 agonist with autoimmune disease modifying activity",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26990079",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "sphingosine 1 phosphate receptor s1pr modulators possess a unique mechanism of action in the treatment of multiple sclerosis ms subtype 1 of the s1pr is expressed on the surface of lymphocytes and is important in regulating egression from lymph nodes the s1pr modulators indirectly antagonize the receptor s function leading to sequestration of lymphocytes in the lymph nodes fingolimod was the first s1pr modulator to receive regulatory approval for relapsing remitting ms after 2 phase iii trials demonstrated potent efficacy safety and tolerability fingolimod can cause undesirable effects as a result of its interaction with other s1pr subtypes which are expressed in diverse tissues including cardiac myocytes as such agents that more selectively target subtype 1 of the s1pr are of interest and are at various stages of development these include ponesimod act128800 siponimod baf312 ozanimod rpc1063 ceralifimod ono 4641 gsk2018682 and mt 1303 data from phase ii trials and early results from phase iii studies have been promising and will be presented in this review of special interest are results from the expand study of siponimod which suggest a potential role for s1pr modulators in secondary progressive ms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28812220",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "the sphingosine 1 phosphate receptor 1 s1p agonist ozanimod ameliorates ulcerative colitis yet its mechanism of action is unknown here we examine the cell subsets that express s1p in intestine using s1p egfp mice the regulation of s1p expression in lymphocytes after administration of dextran sulfate sodium dss after colitis induced by transfer of cd4 cd45rb cells and by crossing a mouse with tnf driven ileitis with s1p egfp mice we then assayed the expression of enzymes that regulate intestinal s1p levels and the effect of fty720 on lymphocyte behavior and s1p expression we found that not only t and b cells express s1p but also dendritic dc and endothelial cells furthermore chronic but not acute inflammatory signals increased s1p expression while the enzymes that control tissue s1p levels in mice and humans with inflammatory bowel disease ibd were uniformly dysregulated favoring synthesis over degradation finally we observed that fty720 reduced t cell velocity and induced s1p degradation and retention of na\u00efve but not effector t cells our data demonstrate that chronic inflammation modulates s1p expression and tissue s1p levels and suggests that the anti inflammatory properties of s1pr agonists might not be solely due to their lymphopenic effects but also due to potential effects on dc migration and vascular barrier function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27049060",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ozanimod rpc1063 is an oral selective modulator of the sphingosine 1 phosphate 1 and 5 receptors under development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease the effects of high fat and low fat meals on the pharmacokinetics pk of a single oral dose of ozanimod were evaluated in 24 healthy volunteers in a randomized open label crossover trial each subject received a 1 mg dose of ozanimod hydrochloride under 3 meal conditions fasted high fat and low fat each separated by 7 days mean plasma concentration time profiles for ozanimod and its active metabolites rp101988 major rp101075 minor were similar under all 3 conditions moreover all pk parameters for ozanimod rp101988 and rp101075 were similar under the 3 meal conditions the 90 confidence intervals cis for the ratios of geometric least squares mean fed fasted were within the equivalence limits of 0 80 to 1 25 for area under the concentration time curve from time 0 to infinity auc and maximum plasma concentration c for ozanimod rp101988 and rp101075 except for the high fat effect on rp101075 c 90 ci 0 76 0 88 given this lack of a food effect on the exposure of ozanimod and its active metabolites ozanimod can be taken without regard to meals.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ozanimod is a novel selective oral sphingosine 1 phosphate 1 and 5 receptor modulator in development for multiple sclerosis and inflammatory bowel disease this randomized double blind placebo controlled positive controlled parallel group thorough qt study characterized the effects of ozanimod on cardiac repolarization in healthy subjects eligible subjects were randomized to 1 of 2 groups ozanimod escalated from 0 25 to 2 mg over 14 days or placebo for 14 days a single dose of moxifloxacin 400 mg or placebo was administered on days 2 and 17 the primary end point was the time matched placebo corrected baseline adjusted mean qtcf \u03b4\u03b4qtcf a total of 113 124 91 1 subjects completed the study the upper limits of the 2 sided 90 confidence intervals for \u03b4\u03b4qtcf for both ozanimod 1 and 2 mg were below the 10 millisecond regulatory threshold no qtcf 480 milliseconds or postdose change in qtcf of 60 milliseconds was observed there was no evidence of a positive relationship between concentrations of ozanimod and its active metabolites and \u03b4\u03b4qtcf although ozanimod blunted the observed diurnal increase in heart rate excursions below predose heart rates were no greater than with placebo results demonstrate that ozanimod does not prolong the qtc interval or cause clinically significant bradycardia supporting ozanimod s evolving favorable cardiac safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D045504"
  ]
}